These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19480822)

  • 1. [EpCAM a proteolytically cleaved oncogene and an excellent therapeutic target in cancer].
    Gires O
    Med Sci (Paris); 2009 May; 25(5):449-50. PubMed ID: 19480822
    [No Abstract]   [Full Text] [Related]  

  • 2. Nuclear signalling by tumour-associated antigen EpCAM.
    Maetzel D; Denzel S; Mack B; Canis M; Went P; Benk M; Kieu C; Papior P; Baeuerle PA; Munz M; Gires O
    Nat Cell Biol; 2009 Feb; 11(2):162-71. PubMed ID: 19136966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis.
    Warneke VS; Behrens HM; Haag J; Krüger S; Simon E; Mathiak M; Ebert MP; Röcken C
    Br J Cancer; 2013 Oct; 109(8):2217-27. PubMed ID: 24008668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of EpCAM in cancer and stem cell signaling.
    Munz M; Baeuerle PA; Gires O
    Cancer Res; 2009 Jul; 69(14):5627-9. PubMed ID: 19584271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
    Yamashita T; Budhu A; Forgues M; Wang XW
    Cancer Res; 2007 Nov; 67(22):10831-9. PubMed ID: 18006828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the relationship among microRNA-181, epithelial cell-adhesion molecule (EpCAM) and beta-catenin in hepatic cancer stem cells.
    Li JP; Zheng JY; Du JJ; Zhang R; Yang AG
    Hepatology; 2009 Dec; 50(6):2047-8; author reply 448. PubMed ID: 19937678
    [No Abstract]   [Full Text] [Related]  

  • 7. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
    Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
    Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis.
    Uekita T; Sakai R
    Cancer Sci; 2011 Nov; 102(11):1943-8. PubMed ID: 21812858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM as a target in cancer therapy.
    Gires O; Bauerle PA
    J Clin Oncol; 2010 May; 28(15):e239-40; author reply e241-2. PubMed ID: 20385979
    [No Abstract]   [Full Text] [Related]  

  • 10. Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2.
    Gao J; Yan Q; Liu S; Yang X
    PLoS One; 2014; 9(7):e102590. PubMed ID: 25019346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.
    Münz M; Zeidler R; Gires O
    Cancer Lett; 2005 Jul; 225(1):151-7. PubMed ID: 15922867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM: another surface-to-nucleus missile.
    Carpenter G; Red Brewer M
    Cancer Cell; 2009 Mar; 15(3):165-6. PubMed ID: 19249674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpCAM in carcinogenesis: the good, the bad or the ugly.
    van der Gun BT; Melchers LJ; Ruiters MH; de Leij LF; McLaughlin PM; Rots MG
    Carcinogenesis; 2010 Nov; 31(11):1913-21. PubMed ID: 20837599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of EpCAM overexpression on human breast cancer cell lines.
    Gostner JM; Fong D; Wrulich OA; Lehne F; Zitt M; Hermann M; Krobitsch S; Martowicz A; Gastl G; Spizzo G
    BMC Cancer; 2011 Jan; 11():45. PubMed ID: 21281469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.
    Trzpis M; McLaughlin PM; de Leij LM; Harmsen MC
    Am J Pathol; 2007 Aug; 171(2):386-95. PubMed ID: 17600130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
    Kurtz JE; Dufour P
    Expert Opin Biol Ther; 2010 Jun; 10(6):951-8. PubMed ID: 20426706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trop2: a possible therapeutic target for late stage epithelial carcinomas.
    Cubas R; Li M; Chen C; Yao Q
    Biochim Biophys Acta; 2009 Dec; 1796(2):309-14. PubMed ID: 19683559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM as Modulator of Tissue Plasticity.
    Fagotto F
    Cells; 2020 Sep; 9(9):. PubMed ID: 32961790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy.
    Yanamoto S; Kawasaki G; Yoshitomi I; Iwamoto T; Hirata K; Mizuno A
    Oral Oncol; 2007 Oct; 43(9):869-77. PubMed ID: 17207659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.
    Simon M; Stefan N; Plückthun A; Zangemeister-Wittke U
    Expert Opin Drug Deliv; 2013 Apr; 10(4):451-68. PubMed ID: 23316711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.